196 results about "Respiratory distress" patented technology

The invention relates to the technical field of biomedical engineering, and discloses an acute respiratory distress syndrome mechanical ventilation adaptive adjustment control system, which comprises a data acquisition module, a signal preprocessing module, a physiological parameter calculation module, a prediction module, a decision and control logic module and the like. Wherein the prediction module predicts a dynamic lung compliance change trend by using a long short-term memory neural network model, and the decision and control logic module generates a ventilation parameter adjustment instruction according to a prediction result and a clinical safety rule. By adopting the technical scheme, the system overcomes the hysteresis of traditional feedback regulation, reduces the risk of breathing machine related lung injury, optimizes oxygenation and carbon dioxide removal efficiency, and provides an accurate, safe and individualized mechanical ventilation treatment scheme.

The invention discloses a risk early warning system based on enteral nutrition management of a patient, and belongs to the technical field of medical technology and biomedicine. A risk early warning system based on enteral nutrition management of a patient comprises a patient monitoring module, a score calculation module, a nutrition control module, an early warning notification module, a nutrition scheme adjustment module and a continuous observation and feedback module. The problems that in the prior art, symptoms of critical patients with the acute respiratory distress syndrome are not monitored in time, the regulation efficiency of enteral nutrition supply is low, errors are prone to occurring, and an early warning mechanism is incomplete are solved. By introducing a real-time monitoring and intelligent quantitative evaluation tool, an automatic regulation and control mechanism and multi-level early warning notification and detailed guidance, main problems existing in enteral nutrition management of the severe patient with the acute respiratory distress syndrome at present are effectively solved, and the rehabilitation process and the treatment effect of the patient are remarkably improved.

A device for delivering at least one gas to a user is described herein. The device includes a body defining: a chamber to receive the gas, an inlet leading into the chamber and an outlet for the user to draw the gas from the chamber. The device also includes a demand valve assembly configured to supply the gas to the chamber. The demand valve assembly includes an intake block, at least one demand valve coupled to the intake block and an actuator positioned within the chamber and coupled to the demand valve. The actuator is configured to move the demand valve into an open position to supply gas to the chamber. The device also includes a diaphragm assembly. The diaphragm assembly includes a diaphragm membrane abutting the actuator and movable downwardly relative to the body when the user draws the gas from the chamber to supply gas to the chamber.

The present invention relates to an inhibitor of C5a activity and an inhibitor of IL-6 activity for use in the treatment of infectious pneumonia and infectious acute respiratory distress syndrome (ARDS). In further aspects administration regimes and kit of parts are referred to.

A respiratory mask or other sealing interface can be used in combination with a nasal cannula or other unsealing interface in providing respiratory therapies for the treatment of COPD or OSA. The mask can act as a pressure vessel over the top of a nasal cannula, with the intention of increasing expiratory pressure whilst allowing the nasal cannula to provide a user with breathing gases of a high humidity and temperature. The ability to selectively apply increased expiratory pressure may be effective in reducing a user's breathing rate and thus beneficial in the treatment of respiratory distress.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating acute respiratory distress syndrome and a preparation and a preparation method thereof, and the traditional Chinese medicine composition is prepared from the following raw materials: 12-30g of ginseng, 6-30 parts of rheum officinale, 9-30 parts of salvia miltiorrhiza and 3-15 parts of semen lepidii. Pharmacological experiments prove that the traditional Chinese medicine composition can improve lung inflammation infiltration to different degrees, improve lung tissue structure disorder and relieve pulmonary edema, and the clinical death rate is remarkably reduced in clinical application; the prepared preparation, especially granules, can be stored for 36 months for a long time, and is suitable for further industrial mass production.

Apparatus and methods are described for continuous and non-invasive detection of (1) respiratory effort, and (2) cellular oxygen requirement compared to cellular oxygen supply. The apparatus is configurable for remote patient care and configured to monitor one or more of sleep disordered breathing, hypertension, heart failure, pneumonia, asthma, chronic obstructive pulmonary disease (COPD), respiratory distress syndrome (RDS) in premature infants, and acute respiratory distress syndrome (ARDS) in children and adults. Additionally, the device is configurable to control delivery of therapy.

The invention discloses an imitated intercorial nano preparation for treating acute respiratory distress syndrome, and belongs to the technical field of biological medicine. The internalized nano preparation comprises an active component, a liposome phospholipid bilayer and a target head, wherein the active component consists of an ROS (reactive oxygen species) removing drug and an anti-inflammatory drug. According to the invention, efficient and accurate targeting of the nano-preparation is realized by innovatively applying an imitated interment effect, an apoptotic cell marker is modified on the surface of the liposome, and an'eat me 'signal is released to simulate a natural biological process that macrophages clear apoptotic cells to be recognized and swallowed by alveolar macrophages, so that efficient and specific targeting is realized, and the targeting effect of the nano-preparation is improved. Meanwhile, up-regulation of PS receptor expression of macrophages at the inflammation part further enhances the targeting effect, and a new way is provided for efficient delivery of acute respiratory distress syndrome medicine preparations and remodeling of pathological microenvironment.

The invention discloses an application of sIL-2R alpha as a marker in a product for early prediction of acute respiratory distress syndrome. The product for early predicting the acute respiratory distress syndrome comprises a reagent or a medicine for detecting the expression level of sIL-2R alpha in a patient with the acute respiratory distress syndrome. The sIL-2R alpha is used as a biomarker, and experiments prove that the sIL-2R alpha level of the plasma of the ARDS patient is obviously higher than that of a patient without ARDS in the plasma of the ARDS patient. By detecting the sIL-2R alpha level of plasma or serum of an ARDS patient, the ARDS occurrence risk is predicted in an early stage, so that individualized intervention treatment is given, the occurrence rate of ARDS can be reduced, and the kit has important clinical application value for improving prognosis of the ARDS patient.

The invention relates to a class of small molecule inhibitors of GPR68 / OGR1, a proton-sensing / stretch-sensing / sheer-stress-sending G-protein coupled receptor, and related receptors GPR4 and GPR65. These inhibitors are useful as a therapeutic for glioblastoma and other neoplasms, as a monotherapy or adjuvant, and also can be used as a treatment for other conditions, such as osteoporosis, inflammatory bowel disease, autoimmune and chronic inflammatory diseases such as multiple sclerosis and inflammatory pain syndromes, GERD, aspiration pneumonitis, bacterial and viral pneumonia, COPD, acute respiratory distress syndrome (ARDS), and COVID-19.

The invention relates to application of bifidobacterium animalis in preparation of a product for preventing, treating or adjunctively treating pneumonia, and belongs to the technical field of microorganisms. The invention aims to solve the technical problem that the existing treatment of acute lung injury (ALI) / acute respiratory distress syndrome (ARDS) is mainly based on supportive means and lacks special-effect treatment drugs. According to the key point of the technical scheme, a new strain, namely the Bifidobacterium animalis ORG01 is provided, the preservation number is GDMCC NO: 67122, and the strain has good technical effects in the aspects of improving the acute lung injury effect, the strain stability, the product application convenience and the like. According to an experimental test, the bifidobacterium animalis ORG01 disclosed by the invention can be used for remarkably recovering the lung organ index of an LPS-induced acute lung injury model mouse, the TNF-alpha content in serum and the mRNA expression level of IL-6 in lung tissues to normal levels.

The invention discloses application of ubiquitin specific protease USP4 in treatment of acute lung injury / acute respiratory distress syndrome. The GEO database analysis finds that USP4 is increased in patients with acute respiratory distress syndrome; the expression level of USP4 is increased by stimulating human neutrophils in vitro with LPS, and experiments prove that the USP4 inhibitor Vialinin A can effectively treat acute lung injury and effectively improve the survival rate of mice; acute lung injury can be effectively relieved by using adenovirus to inhibit expression of USP4 in lung; the USP4 defect of the hematopoietic system can effectively relieve acute lung injury. The application of the USP4 serving as the target spot in screening the medicine for treating the acute lung injury or the acute respiratory distress syndrome is provided for the first time, a new target spot is provided for treating the acute lung injury or the acute respiratory distress syndrome, and a new treatment strategy is provided for clinical treatment.

The invention provides a neonatal acute respiratory distress syndrome antenatal prediction model, which is characterized in that 15 key variables for predicting neonatal acute respiratory distress syndrome are screened out by using an LASSO regression algorithm according to perinatal high-risk factors; and taking the key variables as input, taking the neonatal acute respiratory distress syndrome as output, and training by using a BP neural network to obtain the neonatal acute respiratory distress syndrome antenatal prediction model. According to the method, personalized early prediction of the NARDS can be realized, and the possibility of occurrence of the neonatal acute respiratory distress syndrome can be predicted before a fetus is born; in the prediction process, the examination result can be obtained only by inputting various existing examination data into the prediction model, the method is simple and easy to operate, visual, reliable and rapid, evaluation can be conducted at any time, and the requirements for professional knowledge of medical staff and hospital instruments and equipment are low.

The present invention relates to the use of an ROR inverse agonist or a pharmaceutically acceptable salt thereof for the preparation of a medicament for modulating ROR in a patient and / or for controlling autoimmune diseases and antibody-mediated rejection in a patient. The ROR-mediated diseases or autoimmune diseases include HIV, cancer, celiac disease, type 1 diabetes, Graves' disease (Graves' disease), inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease (Crohn's disease), cardiovascular disease, inflammatory disease, nervous system disorders, multiple sclerosis, and the like. Acute respiratory distress syndrome and arteriosclerosis.

Generally, the present disclosure is directed to methods of producing Resolvin-loaded extracellular vesicles, compositions comprising Resolvin-loaded extracellular vesicles, and methods of treating diseases using such compositions. In some embodiments, methods described herein comprise providing a population of cells, transfecting the population of cells with at least one plasmid vector encoding human cyclooxygenase-2 and 5-lipoxygenase, applying DHA, EP A, and ASA to the transfected population of cells, and isolating the Resolvin-loaded extracellular vesicles from culture media of the transfected population of cells. In some cases, a composition described herein comprises a plurality of extracellular vesicles comprising at least one Resolvin packaged within an interior of the EVs. In some embodiments, upon disposing a plurality of Resolvin-loaded extracellular vesicles within a biological compartment of the patient, inflammation from an inflammatory condition or disease, such as acute lung respiratory distress syndrome, is mitigated or resolved.

The invention relates to a crystal form of a compound shown as a formula I or a pharmaceutically acceptable salt thereof and a preparation method of the crystal form of the compound shown as the formula I or the pharmaceutically acceptable salt thereof. The compound of the formula I or the pharmaceutically acceptable salt thereof is used for treating cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, heart failure, pulmonary arterial hypertension (WHO levels I, II, III, IV), angina pectoris, thrombus, restenosis, myocardial infarction, stroke, cardiac insufficiency, fibrosis, pulmonary hyperplasia, erectile dysfunction, asthma, chronic kidney disease, diabetes, and the like. The composition can be used for treating liver cirrhosis, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, acute lung injury, pulmonary fibrosis, cystic fibrosis or interstitial lung disease.

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g.,respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).

Methods and compositions comprising free fatty acids for the treatment, including prevention, of viral infections, including the treatment of Acute Respiratory Distress Syndrome (ARDS). The compositions comprising free fatty acids, optionally linolenic acid, linoleic acid, and / or palmitic acid, may be used in methods for treating viral infections, optionally, coronavirus infections, for example, SARS-CoV, MERS-CoV, and / or SARS-CoV-2 / COVID-19, and influenza virus infections, optionally, H1N1 and / or H5N1.

The application discloses application of a pyrimidinotriazine diketone derivative in preparation of a medicine for inhibiting activity of human protease caspase-1, and belongs to the technical field of medicines. In view of defects of existing caspase-1 inhibitors, the compound has the characteristics of high affinity binding to caspase-1 (K D = 8.11 μM; 8.78 μM) and strong inhibition on the activity (IC 50 = 11.90 nM-14.47 nM). The compound is used for preparation of a medicine for inhibiting the activity of caspase-1 and a medicine for treating inflammation-related diseases such as sepsis-related lung injury, acute respiratory distress syndrome or acute pancreatitis.

Ventilation methods and devices are described. The methods and devices can be used for treating respiratory diseases such as adult respiratory distress syndrome (ARDS). Embedded control software managing various functionalities of the disclosed ventilators is also presented.

According to a first aspect there is provided a portable emergency automatic ventilation device for use by untrained personnel, configured for CPR, relief of respiratory distress of a patient, and both, comprising: a blower / compressor connectable to a patient ventilation tube; a control unit comprising executable programs for regulating airflow and pressure; at least one air flow sensor for detecting inspiration and expiration; and, at least one pressure sensor for detecting pressure; wherein the compressor is programmable to deliver biphasic positive airway pressure (BiPAP) at a first inspiratory positive airway pressure (IPAP) and a second expiratory positive airway pressure, (EPAP), and the control unit comprises a manual selector for switching between the executable programs selected from predetermined CPR operative program instructing T mode ventilation and a respiratory distress operative program providing an S / T mode ventilation. A ventilation kit for use by untrained personnel configured for CPR, relief of respiratory distress of a patient, and both, and methods of using thereof, are also provided.

The present invention relates to the use of antisecretory factor (AF) protein, homologues, and / or fragments thereof, having equivalent functional activity, and / or a pharmaceutically active salt thereof, for restoring and / or normalizing epithelial barrier function for treating and / or preventing acute respiratory failure.In particular, antisecretory factor (AF) protein, homologues, and / or fragments thereof, having equivalent functional activity, and / or a pharmaceutically active salt thereof, is (are) herein disclosed to be of use in counteracting and / or normalizing fluid transfer across epithelial cell barriers with a significant impact on a large proportion of patients with traumatic lung injury, such as but not limited to patients suffering from abnormal accumulation of fluid in the lung alveoli and / or bronchioles selected from the list of patients suffering from BPD, ARDS, IRDS, sepsis, SIRS, acute pulmonary edema, pneumonia, interstitial pulmonary edema and cardiovascular lung disorder.

The invention relates to the technical field of bioengineering, in particular to a targeting nanoparticle for treating acute respiratory distress syndrome as well as a preparation method and application of the targeting nanoparticle. Comprising the following steps: (1) combining MP peptide with DSPE-PEG2000-MAL through a maleimide-mercaptan reaction, dialyzing the obtained conjugate, washing, and freeze-drying, so as to obtain a DSPE-PEG2000-MP conjugate; and (2) mixing the conjugate, lipid, a pharmaceutical preparation and a solvent, removing the solvent to obtain a lipid film, hydrating the lipid film, and performing membrane extrusion to obtain the nanoparticles. The invention not only provides a novel efficient and safe ARDS treatment scheme, but also provides an innovative mode for the design of a nano-drug delivery system based on cell mediation. And due to the dual targeting capability, excellent anti-inflammatory efficiency and good biocompatibility, the nano-material has a wide prospect in clinical application.

Methods for treating respiratory distress such as ARDS using foaming agent(s) (e.g., natural and / or synthetic surfactant(s)) and / or external energy (e.g., vibration, acoustic, etc.) and compositions and systems configured for performing the same.

The invention provides a respiratory distress treatment auxiliary device, and relates to the technical field of respiratory distress syndrome treatment. A heating seat is mounted at the top of the right side of the breathing machine main body; six auxiliary heating plates are arranged in each of the large water box and the small water box; the top of the large water box and the top of the small water box are each fixedly provided with a positioning frame. An air inlet circular pipe is arranged on the left side of the top of each of the large water box and the small water box; the right side of the top of the large water box and the right side of the top of the small water box are each provided with an air outlet round pipe. An air outlet sleeve is arranged on the inner side of the top of the breathing machine main body; and an air outlet square pipe is slidably mounted on the right side in the air outlet sleeve. When the water box is installed, a connecting pipeline on the breathing machine does not need to be adjusted or replaced, use is more convenient and faster, the heating effect can be improved, the temperature of air guided out through the water box is more stable, and the breathing comfort of a patient is improved.

The invention discloses a non-contact breathing state monitoring method based on a millimeter wave radar, and belongs to the technical field of non-contact human body vital sign monitoring. The method comprises the steps that radar echo signals of a human body target are collected through a millimeter wave radar, a phase sequence is obtained through frequency mixing, filtering and phase demodulation, and breathing signals are extracted through phase unwrapping and displacement conversion; fourier transform is carried out on the respiratory signals, and the respiratory frequency and amplitude are calculated; a plurality of slope extraction algorithms are adopted, derivation is conducted on the respiration signals in the inspiration and expiration stages, and the respiration slope is obtained; and finally, integrating the respiratory rate, the amplitude and the slope, setting a threshold value and a scoring system, and quickly and accurately evaluating the respiratory distress degree. The method does not need to contact a human body, can penetrate through clothes, is suitable for various scenes such as clinical monitoring and emergency triage, and has the advantages of being easy and convenient to operate, high in real-time performance and high in reliability.

The invention provides application of a mitochondrial uncoupling agent BAM15 in preparation of a medicine for treating acute lung injury / acute respiratory distress syndrome (ALI / ARDS), and the BAM15 can improve lung injury of an organism by maintaining dynamic balance of mitochondria, reducing neutrophil apoptosis delay, relieving oxidative stress and autophagy response and inhibiting a cGAS-STING signal channel. The mitochondrial uncoupling agent BAM15 is used for treating acute lung injury / acute respiratory distress syndrome (ALI / ARDS), has the advantages of lower cytotoxicity, no interference on plasma membrane potential, wider treatment window and higher safety, and also has the advantages of delayed administration effectiveness, high treatment efficiency and the like, so that the mitochondrial uncoupling agent BAM15 can be applied to treatment of acute lung injury / acute respiratory distress syndrome (ALI / ARDS). The compound is a promising candidate drug for treating acute lung injury / acute respiratory distress syndrome (ALI / ARDS), and is beneficial to relieving mitochondrial injury, maintaining lung cell functions and reducing inflammatory response related to ALI / ARDS.

Provided are compounds, compositions, and methods for re-polarizing tumor-associated macrophages (TAMs), reducing macrophage-mediated inflammation, and treating diseases. The compound or pharmaceutical composition can be administered to a subject in need thereof, the compound comprising a polymeric carbohydrate backbone and one or more mannose-binding C-type lectin receptor targeting moieties, and the therapeutic agent comprising one or more reactive hydroxyl groups and being attached to the polymeric carbohydrate backbone via a cleavable linker. The cleavable linker can comprise one or more carbonate and / or disulfide moieties. Diseases to be treated can include cancer, autoimmune diseases, inflammatory disorders, non-alcoholic steatohepatitis (NASH), acute respiratory distress syndrome (ARDS), sepsis, coronavirus infection, influenza infection, cytokine storm, and other macrophage-related diseases.

Compositions and methods for treating chronic obstructive pulmonary disease, interstitial lung disease, asthma, bronchitis, pneumonia, cystic fibrosis, pulmonary edema, sarcoidosis, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, acute respiratory distress syndrome, and respiratory syncytial virus in a patient are presented. Embodiments of the composition include a combination of diethylcarbamazine (DEC) and a prostacyclin analogue, such as Beraprost, Beraprost sodium, Iloprost, Treprostinil, Treprostinil Palmitil, and Cicaprost. Other embodiments include fluvoxamine and / or a phosphodiesterase (PDE) inhibitor. Some embodiments of the composition are in the form of an aerosol, include a propellent, or are in an inhalation delivery device.

The invention discloses application of a vitex negundo prevention preparation in preparation of a medicine for treating new crown sequelae and a preparation method of the vitex negundo prevention preparation, and belongs to the field of medicines. The negundo chastetree fruit prevention preparation is prepared from eleven raw medicinal materials including negundo chastetree fruit, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis, radix bupleuri, radix peucedani, ligusticum wallichii, fructus aurantii, poria cocos, platycodon grandiflorum, liquorice and the like, and has the effects of inducing sweat, dispelling exogenous evils, dispelling wind and clearing damp. The negundo chastetree prevention preparation is an effective formula for treating new crown sequelae, can effectively treat viral myocarditis in the recovery period of new crown patients, and can reduce serum concentration of liver function markers ALT and AST and kidney function markers Cre and BUN, so that liver and kidney functions are effectively protected, inflammatory response of acute respiratory distress syndrome is effectively inhibited, diarrhea is effectively treated, and the curative effect is good. And the traditional Chinese medicine composition has an exact treatment effect on the new crown sequelae.